Product Information

LAMICTAL XR 25 MG TABLET is a brand product labeled by GlaxoSmithKline LLC, priced at $14.2042 per EA under NDC 00173075400. Its NADAC has been published 287 times since Nov 28, 2013.

FDA first approved this application on May 29, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the lamotrigine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

Price Statistics

The NADAC for LAMICTAL XR 25 MG TABLET has been published 287 times since Nov 28, 2013, and over the history we have for it it has risen 134.2%. The table below summarizes its recorded NADAC range and movement.

Generic Alternatives

The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.